Itziar Salaverria

List of Publications by Year
in descending order

79 papers	6,905 citations	81434 41 h-index	75989 78 g-index
79 all docs	79 docs citations	79 times ranked	8883 citing authors

#	Article	IF	Citations
1	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Advances, 2022, 6, 2361-2372.	2.5	26
2	A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. Blood Advances, 2022, 6, 4661-4674.	2.5	19
3	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica, 2021, 106, 2682-2693.	1.7	44
4	The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Advances, 2021, , .	2.5	16
5	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. Blood, 2021, 138, 1326-1326.	0.6	1
6	Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma. Haematologica, 2020, 105, e408-e411.	1.7	13
7	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Advances, 2020, 4, 5652-5665.	2.5	67
8	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood, 2020, 135, 274-286.	0.6	81
9	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica, 2019, 104, 1822-1829.	1.7	71
10	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1â^' mantle cell lymphoma. Blood, 2019, 133, 940-951.	0.6	77
11	A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Modern Pathology, 2018, 31, 732-743.	2.9	42
12	CREBBP gene mutations are frequently detected in in situ follicular neoplasia. Blood, 2018, 132, 2687-2690.	0.6	36
13	Novel Double Factor PGT strategy analyzing blastocyst stage embryos in a single NGS procedure. PLoS ONE, 2018, 13, e0205692.	1.1	10
14	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica, 2017, 102, e360-e363.	1.7	27
15	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 2017, 130, 323-327.	0.6	69
16	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. American Journal of Surgical Pathology, 2017, 41, 877-886.	2.1	19
17	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<scp>DLBCL</scp>) reveals gain at 1q31 and <scp>RGS</scp>1 encoding protein; high <scp>RGS</scp>1 immunohistochemical expression associates with poor overall survival in <scp>DLBCL</scp> not otherwise specified (<scp>NOS</scp>). Histopathology, 2017, 70, 595-621.	1.6	41
18	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood, 2016, 128, 1101-1111.	0.6	115

#	Article	IF	Citations
19	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. Cell Reports, 2016, 16, 2061-2067.	2.9	58
20	Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell, 2016, 30, 806-821.	7.7	103
21	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. American Journal of Surgical Pathology, 2016, 40, 192-201.	2.1	40
22	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. Annals of Hematology, 2016, 95, 253-262.	0.8	19
23	Detection of chromothripsisâ€like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2015, 54, 668-680.	1.5	23
24	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	13.7	749
25	Checkâ€™-ing DLBCL. Oncoscience, 2015, 2, 71-72.	0.9	1
26	Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections. American Journal of Surgical Pathology, 2014, 38, 86-93.	2.1	58
27	Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nature Biotechnology, 2014, 32, 1106-1112.	9.4	74
28	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 2014, 99, e231-e234.	1.7	33
29	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood, 2014, 123, 1187-1198.	0.6	185
30	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget, 2014, 5, 726-739.	0.8	25
31	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget, 2014, 5, 6788-6800.	0.8	32
32	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. Blood, 2014, 124, 1677-1677.	0.6	4
33	High resolution copy number analysis of IRF4 translocationâ€positive diffuse large Bâ€cell and follicular lymphomas. Genes Chromosomes and Cancer, 2013, 52, 150-155.	1.5	30
34	microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics. Clinical Cancer Research, 2013, 19, 3121-3129.	3.2	35
35	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	9.4	179
36	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	3.3	488

#	Article	IF	Citations
37	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica, 2013, 98, 1237-1241.	1.7	65
38	CCND2 rearrangements are the most frequent genetic events in cyclin D1â˜' mantle cell lymphoma. Blood, 2013, 121, 1394-1402.	0.6	183
39	Follicular Lymphomas in Children and Young Adults. American Journal of Surgical Pathology, 2013, 37, 333-343.	2.1	149
40	Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. Cancer Research, 2012, 72, 5307-5316.	0.4	231
41	Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood, 2012, 120, 2395-2404.	0.6	132
42	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood, 2012, 119, 1882-1887.	0.6	163
43	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. Journal of Applied Genetics, 2012, 53, 167-174.	1.0	35
44	The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric Bâ€cell lymphoma with germinal center phenotype. Genes Chromosomes and Cancer, 2012, 51, 338-343.	1.5	18
45	The Gray Zone Between Burkitt's Lymphoma and Diffuse Large B-Cell Lymphoma From a Genetics Perspective. Journal of Clinical Oncology, 2011, 29, 1835-1843.	0.8	104
46	Follicular lymphoma grade 3B. Best Practice and Research in Clinical Haematology, 2011, 24, 111-119.	0.7	21
47	Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. PLoS ONE, 2011, 6, e21382.	1.1	38
48	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood, 2011, 118, 139-147.	0.6	281
49	Response: proliferative versus functional anergy. Blood, 2011, 118, 3442-3442.	0.6	16
50	A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma. Blood, 2011, 118, 3442-3444.	0.6	36
51	The complex landscape of genetic alterations in mantle cell lymphoma. Seminars in Cancer Biology, 2011, 21, 322-334.	4.3	100
52	Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica, 2011, 96, 1327-1334.	1.7	142
53	Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica, 2011, 96, 262-268.	1.7	92
54	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leukemia and Lymphoma, 2011, 52, 2226-2236.	0.6	29

#	Article	IF	Citations
55	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Modern Pathology, 2011, 24, 1586-1597.	2.9	137
56	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood, 2010, 116, 953-961.	0.6	122
57	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451.	1.5	68
58	Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica, 2010, 95, 253-259.	1.7	107
59	Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. Leukemia and Lymphoma, 2010, 51, 1612-1622.	0.6	21
60	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.4	78
61	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood, 2009, 114, 826-834.	0.6	177
62	Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood, 2009, 113, 3059-3069.	0.6	162
63	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes and Cancer, 2008, 47, 1086-1097.	1.5	28
64	Genomic profiling reveals different genetic aberrations in systemic ALKâ€positive and ALKâ€negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526.	1.2	145
65	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica, 2008, 93, 1327-1334.	1.7	80
66	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 132-136.	1.7	17
67	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expressionâ€"Based Proliferation Signature. Journal of Clinical Oncology, 2007, 25, 1216-1222.	0.8	166
68	Leukemic involvement is a common feature in mantle cell lymphoma. Cancer, 2007, 109, 2473-2480.	2.0	82
69	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. Blood, 2007, 110, 360-360.	0.6	7
70	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. Blood, 2007, 110, 1585-1585.	0.6	0
71	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leukemia Research, 2006, 30, 923-934.	0.4	45
72	Analysis ofAurora-A andhMPS1 mitotic kinases in mantle cell lymphoma. International Journal of Cancer, 2006, 118, 357-363.	2.3	28

#	Article	IF	Citations
73	Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. International Journal of Cancer, 2006, 119, 2768-2774.	2.3	32
74	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica, 2006, 91, 11-6.	1.7	135
75	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 2005, 107, 1101-1107.	0.6	68
76	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 2005, 106, 3183-3190.	0.6	348
77	Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2004, 22, 3498-3506.	0.8	87
78	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415.	0.6	1
79	Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica, 2004, 89, 1322-31.	1.7	19